TNGX
Tango Therapeutics Inc.
Company Overview
| Mkt Cap | $1.05B | Price | $19.80 |
| Volume | 1.89M | Change | +0.00% |
| P/E Ratio | -8.0 | Open | $20.23 |
| Revenue | $42.1M | Prev Close | $19.80 |
| Net Income | $-130.3M | 52W Range | $1.03 - $22.20 |
| Div Yield | N/A | Target | $21.40 |
| Overall | 55 | Value | 45 |
| Quality | 57 | Technical | 63 |
No chart data available
About Tango Therapeutics Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Latest News
Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNGX | $19.80 | 0% | 1.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |